CD274 and chronic myelogenous leukemia, BCR-ABL1 positive: Few clinical observations have been published or presented, but a phase 1 trial using PD-L1 inhibitor nivolumab in combination with dasatinib has recently been completed with results pending (ClinicalTrials.gov Identifier: NCT02011945) and PD-L1 inhibitor avelumab is under investigation for CML patients in the ACTIW trial (ClinicalTrials.gov Identifier: NCT02767063).